QAdvis acquired by Labquality
Our role
Evli Corporate Finance acted as exclusive financial adviser to Labquality in the acquisition of QAdvis.
Labquality strengthens its regulatory affairs service capabilities and expands to Sweden by acquiring QAdvis, supported by
Buyer
Labquality
Labquality comprises of a team of experienced experts in healthcare and health-tech quality. The company’s quality services for the healthcare, pharmaceutical and medical technology industries cover external quality assessments, regulatory consulting, clinical investigations and trials, audits and certifications, and training. Labquality’s expertise and knowledge benefit medical device and in vitro diagnostic manufacturers, pharmaceutical companies, healthcare units, and clinical laboratories.
Currently, Labquality serves customers in over 60 countries and the team comprises 150 skilled professionals with offices in Finland, Poland, and Germany.
Mérieux Equity Partners
Founded in 2009, Mérieux Equity Partners (“MxEP”) is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and products or services transformative for Health. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM. Labquality has been supported by Mérieux Equity Partners since November 2023.
Target
QAdvis specializes in quality management and regulatory affairs services for medical device and in vitro diagnostic device manufacturers. The company has a strong position in the Swedish quality and regulatory affairs services market. QAdvis also has broad experience and know-how in medical device software, from risk management and validation to quality assurance. The acquisition aligns with Labquality’s international growth strategy and enables Labquality to enter and grow its business in Sweden.